title: Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
abstract: The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit.
authors.affiliation: University of California, San Francisco School of Medicine, San Francisco, California 94110, USA. dwaters@medsfgh.ucsf.edu
authors.forename: David D
authors.initials: DD
authors.lastname: Waters
authors.forename: John R
authors.initials: JR
authors.lastname: Guyton
authors.forename: David M
authors.initials: DM
authors.lastname: Herrington
authors.forename: Mary P
authors.initials: MP
authors.lastname: McGowan
authors.forename: Nanette K
authors.initials: NK
authors.lastname: Wenger
authors.forename: Charles
authors.initials: C
authors.lastname: Shear
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000401:mortality; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006323:Heart Arrest / Q000453:epidemiology; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000453:epidemiology; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin